January 10, 2019 / 10:52 AM / 10 days ago

BRIEF-New England Journal Of Medicine Publishes Positive Results Of Cablivi (Caplacizumab) Trial

Jan 10(Reuters) - SANOFI SA:

* ANNOUNCED ON WEDNESDAY THAT HERCULES PHASE 3 TRIAL MET ITS PRIMARY ENDPOINT

* CABLIVI WAS ASSOCIATED WITH SIGNIFICANT REDUCTION IN ATTP-RELATED DEATH, RECURRENCE, OR AT LEAST ONE MAJOR THROMBOEMBOLIC EVENT WHILE PATIENTS WERE ON TREATMENT

* DURING THE OVERALL STUDY PERIOD, PATIENTS EXPERIENCED A SIGNIFICANTLY LOWER NUMBER OF ATTP RECURRENCES (67 PERCENT REDUCTION) COMPARED TO PLACEBO (P<0.001)

* RESULTS SHOWED CLINICALLY MEANINGFUL REDUCTION IN THE USE OF PLASMA EXCHANGE IN PATIENTS TREATED (AVERAGE 5.8 DAYS; 38 PCT REDUCTION) VERSUS PLACEBO (9.4 DAYS)

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below